FDA is launching real-time monitoring of drug trials, with AstraZeneca and Amgen as first test cases
The FDA is implementing a new system for real-time monitoring of clinical drug trials, starting with pilot programs involving pharmaceutical companies AstraZeneca and Amgen. This initiative aims to improve data transparency, trial oversight, and patient safety throughout the drug development process. The system will allow regulators to access trial data as it is generated, rather than in periodic submissions. The move represents a shift toward more proactive and efficient regulatory review.
- ▪The FDA is launching a real-time monitoring system for clinical drug trials.
- ▪AstraZeneca and Amgen are the first companies participating in the pilot program.
- ▪The system enables continuous data sharing between companies and regulators during trials.
- ▪The goal is to enhance patient safety, data integrity, and regulatory efficiency.
- ▪Real-time access could speed up the identification of safety issues and streamline approvals.
Opening excerpt (first ~120 words) tap to expand
Why have I been blocked? This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.
Excerpt limited to ~120 words for fair-use compliance. The full article is at Qz.
Discussion
0 commentsMore from Qz
